Shionogi to pay $2B for IntraBio, a commercial rare disease biotech

EndpointsView source article

Part of story

Shionogi to acquire IntraBio for $2 billion

Japanese pharmaceutical company Shionogi has agreed to acquire American biotech IntraBio for $2 billion, gaining global rights to Aqneursa, a treatment for rare neurological conditions.

Oct 5, 20263 sourcesDrug development Neurological disorders

Shionogi to acquire IntraBio for $2 billion

Other sources for this story

BioPharma Dive

Shionogi pays $2B to acquire a rare disease startup

The Wall Street Journal

Shionogi to pay $2B for IntraBio, a commercial rare disease biotech

Part of story

Shionogi to acquire IntraBio for $2 billion

Other sources for this story

Shionogi pays $2B to acquire a rare disease startup

Shionogi to Acquire IntraBio for $2 Billion

Shionogi to pay $2B for IntraBio, a commercial rare disease biotech

Part of story

Shionogi to acquire IntraBio for $2 billion

Other sources for this story

Shionogi pays $2B to acquire a rare disease startup

Shionogi to Acquire IntraBio for $2 Billion